A Short Approach to *N*-Aryl-1,2,3,4-tetrahydroisoquinolines from *N*-(2-Bromobenzyl)anilines via a Reductive Amination/Palladium-Catalyzed Ethoxyvinylation/Reductive *N*-Alkylation Sequence

Carina Glas

Rický Wirawan

Franz Bracher*

Department of Pharmacy – Center for Drug Research,
Ludwig-Maximilians University Munich, Butenandtstr.
5-13, 81377 Munich, Germany
Franz.Bracher@cup.uni-muenchen.de

Received: 20.10.2020

Accepted after revision: 30.11.2020

Published online: 07.01.2021

DOI: 10.1055/s-0040-1706002; Art ID: ss-2020-z0544-op

Abstract *N*-Aryl-1,2,3,4-tetrahydroisoquinolines are obtained via a convenient and short protocol with a broad range of substituents on both aromatic rings and high functional group tolerance. Starting from readily available *ortho*-brominated aromatic aldehydes and primary aromatic amines, condensation of these building blocks under reductive conditions gives *N*-aryl 2-bromobenzylamines. The C-3/C-4-unit of the tetrahydroisoquinoline is introduced using commercially available 2-ethoxyvinyl pinacolboronate under Suzuki conditions. Finally, the obtained crude *ortho*-ethoxyvinyl benzylamines are cyclized via an intramolecular reductive amination using the combination of triethylsilane/TFA to give the desired *N*-aryl-1,2,3,4-tetrahydroisoquinolines.

Key words *N*-aryl-1,2,3,4-tetrahydroisoquinolines, reductive cyclization, Pd-catalyzed ethoxyvinylation, reductive *N*-alkylation, cross-coupling

The isoquinoline ring system is an important structural motif in bioactive heterocycles. Due to its biosynthetic origin from amino acid derived arylethylamine precursors, 1-substituted 1,2,3,4-tetrahydroisoquinolines (especially 1-benzyl derivatives) are a dominant structural element in isoquinolines obtained from natural sources, and compounds of this chemotype show a wide spectrum of biological activity.¹

In contrast, *N*-aryl-1,2,3,4-tetrahydroisoquinolines are rather underexplored. Diverse biological activities have been reported for this chemotype, mostly in patents, e.g., the inhibition of enzymes such as cathepsin B and calpain-2,^{2a} tumor-relevant NADPH quinone oxidoreductase and *E. coli* nitroreductase,^{2b} blocking of P-gp efflux pumps in tumor cells,^{2c} and modulation of potassium and sodium channels leading to antiepileptic^{2d} and analgesic effects, respec-

tively.^{2e} Further, *N*-aryl-1,2,3,4-tetrahydroisoquinolines have been described as ligands for estrogen receptors,^{3a} G-protein coupled receptors,^{3b} and serotonin transporters.^{3c}

Whereas common 1-substituted 1,2,3,4-tetrahydroisoquinolines are readily available starting from arylethylamines through established cyclization reactions (Pictet-Spengler, Bischler-Napieralski, followed by reduction)⁴ or through controlled reduction of fully aromatic isoquinolines,⁵ to date, there are only a limited number of published synthetic routes to *N*-aryl-1,2,3,4-tetrahydroisoquinolines. These include mainly *N*-arylations of 1,2,3,4-tetrahydroisoquinolines utilizing aryl bromides or iodides under palladium (Buchwald-Hartwig reaction)^{6a,b} or copper catalysis (Ullmann reaction);^{6c} alternatively, arylboronic acids or trifluoroborates were coupled under copper catalysis.^{6d} Transition-metal-free *N*-arylations can be achieved with reactive aryl halides^{2b} or by using in situ prepared arynes^{6e} (with associated regioselectivity issues). Other procedures involving the *de novo* construction of the 1,2,3,4-tetrahydroisoquinoline ring system via incorporation of primary aromatic amines are less convenient as they require either hazardous (*ortho*-halomethyl-arylethyl halides)⁷ or poorly accessible (benzo-anellated dihydropyrans)^{7b,c} starting materials (Figure 1). A Pomeranz-Fritsch-type cyclization of *N*-aryl-*N*-benzylaminoacetaldehyde acetals to 4-hydroxy-*N*-aryl-1,2,3,4-tetrahydroisoquinolines is hampered by the strongly acidic conditions required and the formation of diverse side products.⁸

Consequently, the development of convenient approaches to *N*-aryl-1,2,3,4-tetrahydroisoquinolines is still a promising task. In continuation of our research on bioactive isoquinolines⁹ we were interested in the synthesis of *N*-aryl-1,2,3,4-tetrahydroisoquinolines as rigid analogues of steroids^{3a} and azobenzenes.¹⁰

Published approaches:

1. *N*-Arylation of tetrahydroisoquinolines

2. Construction of the isoquinoline ring system

New approach:

Figure 1 Published approaches to *N*-aryl-1,2,3,4-tetrahydroisoquinolines and the retrosynthetic concept of the new approach reported herein

In order to achieve a short approach to the target *N*-aryl-1,2,3,4-tetrahydroisoquinolines and related ring systems with maximum variability in both aromatic rings, we have developed a novel modular method starting from *ortho*-brominated aromatic aldehydes and primary aromatic amines (Figure 1). Both of these building blocks are readily available with a broad variety of additional substituents on the rings. Condensation of these building blocks under reductive conditions would give *N*-aryl 2-bromobenzylamines. The missing C-3/C-4-unit of the isoquinoline was to be introduced using commercially available 2-ethoxyvinyl pinacolboronate under Suzuki conditions.^{9b,11} Finally, the obtained *ortho*-ethoxyvinyl *N*-arylbenzylamine would undergo an intramolecular reductive amination using the combination of triethylsilane/trifluoroacetic acid (TFA) to give the desired *N*-aryl-1,2,3,4-tetrahydroisoquinolines. Similar *N*-arylethylations of aromatic amines using enol ethers have recently been performed in our group for the synthesis of arylethylated anilines and *N*-heterocycles.¹² In a similar manner, benzodiazepines were obtained by intramolecular reductive amination with acetals,¹³ and intermolecular *N*-alkylations using silane/TFA reagents were accomplished with acetals^{14a} and free aldehydes.^{14b}

We performed our pilot experiment with 2-bromobenzaldehyde (**1**) and aniline (**2**) (Scheme 1; reactions are depicted with optimized conditions). For the first step, the intermolecular reductive amination, we employed standard conditions utilizing NaCNBH₃ as the reducing agent and obtained *N*-phenyl 2-bromobenzylamine (**3a**) in quantitative yield. For the subsequent *de novo* construction of the *N*-aryl-1,2,3,4-tetrahydroisoquinoline ring system, we investigated different conditions in order to optimize the yield and to reduce waste, purification efforts and workload (Table 1 and Scheme 1).

First, the Suzuki reaction was performed according to an established protocol from our previous work^{9b,11} using 2-ethoxyvinyl pinacolboronate, tetrakis(triphenylphosphine)palladium(0) and cesium carbonate (Scheme 1). The formation of enol ether **4a** could be monitored by TLC. We decided not to purify the intermediate *ortho*-ethoxyvinyl benzylamine **4a**, but only isolated the crude organic material after aqueous work-up and then re-dissolved it in dichloromethane (DCM), an established solvent for silane/TFA reductions. For the reductive cyclization of crude **4a** we examined procedures derived from similar *N*-arylethylation reactions,^{12a,13} as shown in Table 1.

Table 1 The Reaction Conditions Explored for the Reductive Cyclization

Entry	Conditions for the cyclization of crude enol ether 4a	Yield of 5a
1 ^{12a}	Et ₃ SiH (10 equiv), TFA (10 equiv), dry DCM, 0 °C, 3.5 h	30% over 2 steps
2 ¹³	Et ₃ SiH (2.5 equiv), TFA (13 equiv), dry DCM, rt, 2.5 h	34% over 2 steps
3	pure 4a , Et ₃ SiH (2.5 equiv), TFA (13 equiv), dry DCM, rt, 2.5 h	41% over 1 step (21% over 2 steps)
4	one-pot, Et ₃ SiH (10 equiv), TFA (13 equiv), 0 °C to rt, 72 h	6% over 2 steps
5 ^{9b}	Et ₃ SiH (0 equiv), TFA (13 equiv), dry DCM, 0 °C, 3.5 h	6% over 2 steps

We first followed the protocol of Vögerl et al.^{12a} and used 10 equivalents of triethylsilane at 0 °C (Table 1, entry 1). The desired *N*-aryl-1,2,3,4-tetrahydroisoquinoline **5a**

Scheme 1 A pilot experiment using 2-bromobenzaldehyde (**1**) and aniline (**2**) for the new synthetic approach to *N*-aryl-1,2,3,4-tetrahydroisoquinolines (illustrated with optimized conditions)

was formed within 3.5 hours in 30% yield, however, a laborious purification by repeated flash column chromatography (FCC) was required due to the necessity to remove excess triethylsilane. To minimize the purification efforts, we explored the conditions described by Popp et al.¹³ (Table 1, entry 2). Here, only 2.5 equivalents of triethylsilane were used, and the reaction was performed at room temperature. TLC monitoring indicated full consumption of the starting material after 2.5 hours, and product **5a** was obtained in a slightly increased yield of 34% after only one round of FCC. To investigate a possible negative impact of residual reagents or impurities from the Suzuki reaction, we purified enol ether **4a** by FCC (50% yield) and then performed the cyclization reaction (Table 1, entry 3) according to the conditions in entry 2. In this case product **5a** was obtained in 41% yield (21% over 2 steps), leading us to the conclusion that

purification of **4a** was not necessary and rather causes a decrease in the overall yield of **5a**.

In another experiment we omitted the solvent change and directly added, in a one-pot procedure, the required reagents for the cyclization (triethylsilane/TFA) into the reaction mixture of the Suzuki coupling (Table 1, entry 4; following the conditions in entry 1). The reaction was stopped after 72 hours as formation of the cyclized product **5a** was not clearly visible by TLC. Nevertheless, after FCC, product **5a** was isolated in a very poor yield of 6%.

The underlying mechanism of the cyclization reaction using triethylsilane/TFA involves β -protonation of the ethoxyvinyl moiety in **4a** giving a carbenium-oxonium ion, a subsequent intramolecular cyclization leading to formation of a C–N bond with the (necessarily unprotonated) amino group, and finally O-protonation, elimination of

Scheme 2 Scope and limitations of the newly developed synthetic approach towards *N*-aryl-1,2,3,4-tetrahydroisoquinolines

ethanol, and hydride transfer from triethylsilane to the resulting iminium ion. This prompted us to examine whether we would obtain the 3,4-dehydro analogue of **5a**, an *N*-aryl-1,2-dihydroisoquinoline, when only TFA, but no triethylsilane was used (Table 1, entry 5; following conditions published for the synthesis of 1-oxo-1,2-dihydroisoquinolines by Schütz et al.^{9b}). Thus crude enol ether **4a** was treated with only TFA at 0 °C, and after 3.5 hours, enol ether **4a** was completely consumed. The only product we could isolate from the product mixture in pure form was, surprisingly, *N*-aryl-1,2,3,4-tetrahydroisoquinoline **5a** in a poor yield of 6% over both steps.

With optimized cyclization conditions in hand, we next applied our newly developed approach for the synthesis of *N*-aryl-1,2,3,4-tetrahydroisoquinolines and related heterocycles starting from differently substituted *ortho*-brominated aromatic aldehydes and primary aromatic amines (Scheme 2).

Overall, this method enabled us to synthesize a variety of *N*-aryl-1,2,3,4-tetrahydroisoquinolines with yields ranging from 24–70% over two steps starting from the corresponding *N*-aryl 2-bromobenzylamines. As shown in Scheme 2 there was a noticeable difference in the yield of the final products depending on the substitution pattern of the starting material. It is important to note that during their investigation on the scope and limitations of the Suzu-

ki-Miyaura coupling, Buchwald et al. came to the conclusion that differently substituted aryl bromides did not affect the yield significantly when coupled with alkenyl boronic acids.¹⁵ Therefore, the herein observed differences supposedly occur mainly during the final cyclization step.

During this work, we observed an increase in the yield of the final products when anilines with electron-withdrawing substituents were used. Product **5k**, carrying an ester group, and halogenated product **5m** were obtained in 70% and 69% yields over two steps, being twice as high compared to that of product **5a** derived from unsubstituted aniline (34% yield over two steps). A similar trend was observed with products derived from 4-methoxyaniline (**5j**, yield 55%) and methoxylated benzaldehydes (**5b**, **5c**, **5d**, yields 48–55%), compared to product **5g** derived from a nitrobenzaldehyde (yield 63%).

Using our approach even products **5e** and **5f** bearing a free phenolic group could be obtained. Tetrahydroisoquinoline **5f** bearing the phenolic group at a remote position was isolated in a good yield of 56% over two steps. In contrast, phenolic product **5e** was only generated in 29% yield. In this case the intermediate enol ether probably underwent, in part, a competing reaction with the hydroxy group at the other *ortho*-position with cyclization to a benzofuran derivative. A comparable cyclization under acidic conditions has been published by Sakamoto et al.¹⁶

Scheme 3 Application of the method toward the rigidized azobenzene analogue *N*-aryl-1,2,3,4-tetrahydroisoquinoline **5o**

However, our newly developed method is not limited to bromobenzaldehydes and anilines as starting materials and was successfully applied utilizing heteroaromatic compounds. Intermediates **3h** (derived from a brominated thiophenecarbaldehyde) and **3n** (derived from 2-aminopyridine) gave the expected cyclization products **5h** and **5n** in 38% and 24% yields, respectively, over two steps. In contrast, 2-bromonicotinaldehyde-derived amine **3i** underwent the Suzuki coupling, but did not result in the desired cyclized 6-phenyl-5,6,7,8-tetrahydro[1,6]naphthyridine (**5i**) using the standard conditions. The unsuccessful formation of the *N*-aryl-tetrahydroisoquinoline derivative here, and the poor yield of *N*-pyridyl-1,2,3,4-tetrahydroisoquinoline (**5n**), might in part be due to counter-productive protonation of the pyridine-containing intermediates by TFA during the cyclization step.

In previous work in this field,^{12a,13,17} we found that *N*-arylethylations utilizing enol ethers and the triethylsilane/TFA reagent mixture were limited to nitrogen compounds of low to very low basicity, like anilines, carbazoles, indoles and phenothiazines. Aliphatic amines, however, are protonated by TFA and hence are prevented from nucleophilic attack at the protonated enol ether, leading to failure of the reaction. This finding was again confirmed in this work during examination of the intermolecular reductive amination with *N*-cyclohexyl-2-bromobenzylamine (**3l**).

The successful Suzuki coupling could again be confirmed by TLC and mass spectrometry, but as expected, subsequent cyclization did not result in the desired *N*-cyclohexyl-1,2,3,4-tetrahydroisoquinoline (**5l**), and only unidentified side products were observed.

During these studies on the scope and limitations of our method, we observed that some of the compounds were air-sensitive and experienced oxidative degradation. Therefore, the final *N*-aryl-1,2,3,4-tetrahydroisoquinolines should be stored under inert gas after their preparation.

In the course of a project aimed at the synthesis of *N*-aryl-1,2,3,4-tetrahydroisoquinolines as rigidized analogues of bioactive azobenzenes,¹⁰ we applied our new approach to the synthesis of analogue **5o**, starting from known acetonide-protected 5-aminosalicylic acid **7**¹⁸ and amide-substituted 2-bromobenzaldehyde **6** (obtained from the corresponding carboxylic acid and β -alanine ethyl ester under standard amidation conditions), introducing two more functional groups for the analysis of the scope and limitations of the novel cyclization method (Scheme 3). The intermolecular reductive amination yielded **3o** in 96% yield. The Suzuki reaction, cyclization and subsequent alkaline deprotection generated target compound **5o** in 60% yield over 3 steps, once again confirming the beneficial effects of electron-withdrawing substituents on the yield of the cyclization. Unfortunately, this product was not stable and had to be analyzed and, if desired, tested shortly after preparation.

In conclusion, we have developed a convenient and short protocol for the synthesis of *N*-aryl-1,2,3,4-tetrahydroisoquinolines and related heterocyclic ring systems possessing a wide range of substituents on both aromatic rings, whilst demonstrating high functional group tolerance. Starting from readily available *ortho*-brominated aromatic aldehydes and primary aromatic amines, the application of reductive conditions allows condensation of these building blocks to give *N*-aryl 2-bromobenzylamines. Commercially available 2-ethoxyvinyl pinacolboronate is then employed under Suzuki conditions to introduce the C-3/C-4-unit of the tetrahydroisoquinoline. Finally, the obtained *ortho*-ethoxyvinyl benzylamines undergo cyclization via an intramolecular reductive amination using triethylsilane/TFA to give the desired *N*-aryl-1,2,3,4-tetrahydroisoquinolines. Notwithstanding that the Suzuki reaction and final cyclization gave only moderate to good yields over two steps, this protocol is more effective than previous approaches to the target chemotype, due to the good availability of the building blocks and the very small number of steps.

Further, compared to previous methods, this protocol yields products of predictable structure; the formation of regioisomeric products is excluded due to the utilization of *ortho*-brominated aromatic aldehydes. In summary, this methodology opens a novel and straightforward access to *N*-aryl-1,2,3,4-tetrahydroisoquinolines and represents an attractive alternative to previous approaches.

(*E*)-2-Ethoxyvinylboronic acid pinacol ester was purchased from Sigma Aldrich. All solvents were purchased from commercial sources and used without further purification. Solvents were dried, if necessary, according to standard methods and stored over activated molecular sieves under a nitrogen atmosphere. Standard vacuum-line techniques were used and glassware was flame-dried prior to use. Organic solvents were dried during workup using phase separation paper. Reactions were monitored via thin-layer chromatography (TLC) using POLYGRAM SIL G/UV₂₅₄ polyester sheets coated with 0.2 mm silica gel (Macherey-Nagel). Plates were visualized using UV light (254 nm or 365 nm) or by staining with 1% aq KMnO₄ or CAM (ceric ammonium molybdate). Monitoring was also performed by mass spectrometry using an atmospheric pressure solids analysis probe (ASAP) with atmospheric pressure chemical ionization (APCI) on an expression LCMS device (Advion, Ithaca, USA). Products were purified by flash column chromatography (normal-phase silica gel chromatography) using SiO₂ 60 (0.040–0.063 mm, 230–400 mesh ASTM) from Merck. Melting points were measured with a Büchi Schmelzpunktapparat B-540 and are reported in °C. Infrared spectra were recorded from 4000 to 650 cm⁻¹ on a PERKIN ELMER Spectrum BX-59343 FT-IR instrument. A Smiths Detection DuraSamp IR II Diamond ATR sensor was used for detection. The absorption bands are reported in wavenumbers (cm⁻¹). NMR spectra (¹H NMR, ¹³C NMR, DEPT, COSY, HSQC, HMBC) were recorded using Avance III HD 400 MHz Bruker BioSpin and Avance III HD 500 MHz Bruker BioSpin spectrometers (¹H NMR: 400 MHz and 500 MHz, ¹³C NMR: 101 MHz and 126 MHz) and the deuterated solvent stated. Chemical shifts (δ) are quoted in parts per million (ppm) and are referenced to the residual solvent peak. Multiplicities are denoted as s (singlet), d (doublet), t (triplet), q (quartet).

and derivatives thereof. Coupling constants J are given in Hz. High-resolution mass spectrometry (HRMS) was performed using a Jeol MStation 700 or JMS GCmate II Jeol instrument for electron impact ionization (EI). A Thermo Finnigan LTQ was used for electrospray ionization (ESI).

Reductive Amination; General Procedure A

The appropriate 2-bromobenzaldehyde (1.2 equiv) and aniline (1.0 equiv) were dissolved in MeOH to a concentration of 0.15 M (with respect to the aniline). A catalytic amount of acetic acid was added, and the reaction mixture stirred at room temperature for 16 h. Sodium cyanoborohydride (3.0 equiv) was added in portions at room temperature. After stirring for an additional 2.5–3 h (TLC monitoring), water was added and the mixture extracted with ethyl acetate ($\times 3$). The combined organic phase was dried using phase separation paper and the solvent was evaporated in vacuo. The crude product was purified by flash column chromatography (FCC) using the indicated eluent.

Suzuki–Miyaura Coupling and Subsequent Cyclization; General Procedure B

The appropriate *N*-(2-bromobenzyl)aniline (1.0 equiv), Pd(PPh₃)₄ (0.1 equiv) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (2.0 equiv) were dissolved in degassed 1,4-dioxane to a concentration of 0.15 M (with respect to the aniline) under a nitrogen atmosphere. The resulting mixture was then stirred for 10 min at room temperature. Cesium carbonate (5.0 equiv) was dissolved in degassed water to a concentration of 0.5 M (with respect to the aniline) under a nitrogen atmosphere and added to the reaction mixture. Stirring was continued at 75 °C for 16–19 h, after which the reaction mixture was allowed to cool to room temperature and sat. aq ammonium chloride solution was added. The organic material was extracted with EtOAc ($\times 3$) and the combined organic phases were dried using phase separation paper. The solvent was removed in vacuo. The crude product was dissolved in dry DCM to a concentration of 0.33 M (with respect to the aniline) under a nitrogen atmosphere. Trifluoroacetic acid (13 equiv) and triethylsilane (2.5 equiv) were added under a nitrogen atmosphere at room temperature in rapid succession. After completion of the reaction (2.5–4.5 h; TLC monitoring), 2 M NaOH was added and the mixture was extracted with DCM ($\times 3$). The combined organic extracts were dried using phase separation paper. The solvent was removed in vacuo and the crude product purified by FCC using the indicated eluent.

N-(2-Bromobenzyl)aniline (3a)

Prepared according to General Procedure A but with 2.0 equivalents of 2-bromobenzaldehyde (**1**) (1.85 g, 10.0 mmol) and aniline (**2**) (456 μ L, 5.00 mmol). The crude product was purified by FCC (hexanes/EtOAc, 95:5) to give product **3a** (1.31 g, 5.00 mmol, quant.) as a white solid.

R_f = 0.25 (hexanes/EtOAc, 95:5); mp 40–42 °C.

IR (ATR): 3381, 3049, 2837, 1601, 1504, 1464, 1433, 1319, 1253, 1178, 1100, 1067, 1043, 1023, 991, 748, 691, 658 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 7.56 (dd, J = 7.9, 1.3 Hz, 1 H, 3'-H), 7.47 (dd, J = 7.7, 1.7 Hz, 1 H, 6'-H), 7.29–7.23 (m, 1 H, 5'-H), 7.22–7.16 (m, 2 H, 2-H and 6-H), 7.13 (td, J = 7.6, 1.8 Hz, 1 H, 4'-H), 6.82–6.76 (m, 1 H, 4-H), 6.73–6.67 (m, 2 H, 3-H and 5-H), 4.43 (s, 2 H, 1'-CH₂).

¹³C NMR (101 MHz, CDCl₃): δ = 146.4 (C-1), 137.4 (C-1'), 133.0 (C-3'), 129.7 (C-6'), 129.5 (C-2 and C-6), 129.1 (C-4'), 127.7 (C-5'), 123.7 (C-2'), 119.1 (C-4), 114.3 (C-3 and C-5), 49.2 (1'-CH₂).

HRMS (ESI): m/z [M + H]⁺ calcd for C₁₃H₁₃BrN⁺: 262.0226; found: 262.0227.

The analytical data are in accordance with those published in the literature.¹⁹

(*E*)-*N*-[2-(2-Ethoxyvinyl)benzyl]aniline (4a)

Under a nitrogen atmosphere, compound **3a** (131 mg, 0.500 mmol), Pd(PPh₃)₄ (57.8 mg, 0.0500 mmol, 10 mol%) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (212 μ L, 1.00 mmol) were dissolved in degassed 1,4-dioxane (3.0 mL) and stirred for 10 min at rt. Under a nitrogen atmosphere, cesium carbonate (815 mg, 2.50 mmol) was dissolved in degassed water (1.0 mL) and added to the reaction mixture. Stirring was then continued at 75 °C for 19 h. The reaction mixture was allowed to cool to room temperature and sat. aq ammonium chloride solution (10.0 mL) was added. The organic material was extracted with EtOAc (3 $\times$ 15.0 mL) and the combined organic phases were dried using phase separation paper. The solvent was removed in vacuo and the crude product was purified by FCC (hexanes/EtOAc, 95:5) to give product **4a** (63.4 mg, 0.250 mmol, 50%) as a yellow oil.

R_f = 0.48 (hexanes/EtOAc, 95:5).

IR (ATR): 3430, 3061, 2976, 1631, 1599, 1507, 1327, 1158, 930, 747, 691 cm⁻¹.

¹H NMR (400 MHz, CDCl₃): δ = 7.34 (ddd, J = 9.3, 7.6, 1.4 Hz, 2 H, 3'-H and 6'-H), 7.25–7.21 (m, 1 H, 4'-H), 7.22–7.18 (m, 2 H, 3-H and 5-H), 7.16 (td, J = 7.5, 1.4 Hz, 1 H, 5'-H), 6.89 (d, J = 12.8 Hz, 1 H, 2''-H), 6.73 (tt, J = 7.3, 1.1 Hz, 1 H, 4-H), 6.67–6.63 (m, 2 H, 2-H and 6-H), 6.05 (d, J = 12.8 Hz, 1 H, 1''-H), 4.28 (s, 2 H, 1'-CH₂), 3.85 (q, J = 7.0 Hz, 2 H, CH₂CH₃), 1.31 (t, J = 7.0 Hz, 3 H, CH₂CH₃).

¹³C NMR (101 MHz, CDCl₃): δ = 149.4 (C-2''), 148.4 (C-1), 135.6 (C-2'), 135.3 (C-1'), 129.4 (C-3 and C-5), 129.2 (C-6'), 127.9 (C-4'), 126.3 (C-5'), 125.5 (C-3'), 117.6 (C-4), 112.9 (C-2 and C-6), 103.0 (C-1'), 65.8 (CH₂CH₃), 46.9 (1'-CH₂), 14.9 (CH₂CH₃).

HRMS (ESI): m/z [M + H]⁺ calcd for C₁₇H₂₀NO⁺: 254.1539; found: 254.1536.

2-Phenyl-1,2,3,4-tetrahydroisoquinoline (5a)

Prepared according to General Procedure B from *N*-(2-bromobenzyl)aniline (**3a**) (131 mg, 0.500 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (212 μ L, 1.00 mmol). The crude product was purified by FCC (hexanes/EtOAc, 95:5) to give product **5a** (35.6 mg, 0.169 mmol, 34%) as a dark yellow-orange oily solid.

R_f = 0.38 (hexanes/EtOAc, 95:5).

IR (ATR): 3023, 2922, 2821, 1661, 1598, 1498, 1460, 1387, 1293, 1212, 1151, 1112, 1034, 989, 935, 741, 690 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 7.32–7.27 (m, 2 H, 3'-H and 5'-H), 7.21–7.15 (m, 4 H, 5-H, 6-H, 7-H and 8-H), 7.01–6.97 (m, 2 H, 2'-H and 6'-H), 6.84 (tt, J = 7.3, 1.1 Hz, 1 H, 4'-H), 4.42 (s, 2 H, 1-H), 3.57 (t, J = 5.8 Hz, 2 H, 3-H), 3.00 (t, J = 5.9 Hz, 2 H, 4-H).

¹³C NMR (126 MHz, CDCl₃): δ = 150.7 (C-1'), 135.0 (C-4a or C-8a), 134.6 (C-4a or C-8a), 129.3 (C-3' and C-5'), 128.7 (C-5), 126.7 (C-8), 126.5 (C-6 or C-7), 126.2 (C-6 or C-7), 118.8 (C-4'), 115.3 (C-2' and C-6'), 50.9 (C-1), 46.7 (C-3), 29.3 (C-4).

HRMS (ESI): m/z [M - H]⁻ calcd for C₁₅H₁₄N⁻: 208.1126; found: 208.1120.

The analytical data are in accordance with those published in the literature.^{6c}

***N*-(2-Bromo-4-methoxybenzyl)aniline (3b)**

Prepared according to General Procedure A from 2-bromo-4-methoxybenzaldehyde (129 mg, 0.600 mmol) and aniline (**2**) (45.6 μ L, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 95:5) to give product **3b** (123 mg, 0.422 mmol, 85%) as a pale yellow solid.

R_f = 0.25 (hexanes/EtOAc, 95:5); mp 69–73 °C.

IR (ATR): 3439, 3062, 2937, 2832, 1601, 1567, 1507, 1486, 1456, 1435, 1319, 1270, 1229, 1176, 1028, 988, 879, 809, 749, 688 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 7.37 (d, J = 8.5 Hz, 1 H, 6'-H), 7.22–7.15 (m, 2 H, 3-H and 5-H), 7.11 (d, J = 2.6 Hz, 1 H, 3'-H), 6.83–6.77 (m, 2 H, 4-H and 5'-H), 6.72 (d, J = 7.7 Hz, 2 H, 2-H and 6-H), 4.37 (s, 2 H, 1'-CH₂), 3.78 (s, 3 H, 4'-OCH₃).

^{13}C NMR (101 MHz, CDCl_3): δ = 159.6 (C-4'), 146.2 (C-1), 130.6 (C-6'), 129.5 (C-3 and C-5), 129.1 (C-1'), 124.1 (C-2'), 119.4 (C-4 and C-5'), 118.3 (C-3'), 114.6 (C-2 or C-6), 113.7 (C-2 or C-6), 55.7 (4'-OCH₃), 48.8 (1'-CH₂).

HRMS (EI): m/z [M]⁺ calcd for C₁₄H₁₄BrNO⁺: 291.0253; found: 291.0253.

6-Methoxy-2-phenyl-1,2,3,4-tetrahydroisoquinoline (5b)

Prepared according to General Procedure B from *N*-(2-bromo-4-methoxybenzyl)aniline (**3b**) (73.0 mg, 0.250 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (106 μ L, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 92:8) to give product **5b** (28.6 mg, 0.120 mmol, 48%) as a yellow solid.

R_f = 0.32 (hexanes/EtOAc, 92:8); mp 39–44 °C.

IR (ATR): 3060, 2933, 2833, 1731, 1597, 1504, 1460, 1388, 1331, 1275, 1227, 1194, 1152, 1032, 913, 849, 805, 751, 690 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 7.32–7.27 (m, 2 H, 3'-H and 5'-H), 7.08 (d, J = 8.4 Hz, 1 H, 8-H), 7.01 (d, J = 8.0 Hz, 2 H, 2'-H and 6'-H), 6.85 (t, J = 6.9 Hz, 1 H, 4'-H), 6.77 (dd, J = 8.4, 2.7 Hz, 1 H, 7-H), 6.70 (d, J = 2.6 Hz, 1 H, 5-H), 4.37 (s, 2 H, 1-H), 3.80 (s, 3 H, 6-OCH₃), 3.56 (t, J = 5.9 Hz, 2 H, 3-H), 2.97 (t, J = 5.9 Hz, 2 H, 4-H).

^{13}C NMR (126 MHz, CDCl_3): δ = 158.2 (C-6), 150.7 (C-1'), 136.2 (C-4a), 129.3 (C-3' and C-5'), 127.6 (C-8), 126.8 (C-8a), 118.8 (C-4'), 115.3 (C-2' and C-6'), 113.3 (C-5), 112.5 (C-7), 55.4 (6-OCH₃), 50.4 (C-1), 46.6 (C-3), 29.5 (C-4).

HRMS (EI): m/z [M – H]⁺ calcd for C₁₆H₁₆NO⁺: 238.1232; found: 238.1227.

***N*-(2-Bromo-5-methoxybenzyl)aniline (3c)**

Prepared according to General Procedure A from 2-bromo-5-methoxybenzaldehyde (129 mg, 0.600 mmol) and aniline (**2**) (45.6 μ L, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 95:5) to give product **3c** (108 mg, 0.370 mmol, 74%) as a yellow oil.

R_f = 0.33 (hexanes/EtOAc, 95:5).

IR (ATR): 3418, 3048, 3003, 2932, 2836, 1600, 1504, 1466, 1432, 1294, 1265, 1240, 1159, 1053, 1015, 868, 803, 747, 691, 600 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 7.43 (d, J = 8.8 Hz, 1 H, 3'-H), 7.22–7.16 (m, 2 H, 3-H and 5-H), 7.05 (d, J = 2.9 Hz, 1 H, 6'-H), 6.78 (t, J = 7.4 Hz, 1 H, 4-H), 6.73–6.66 (m, 3 H, 2-H, 6-H and 4'-H), 4.38 (s, 2 H, 1'-CH₂), 3.74 (s, 3 H, 5'-OCH₃).

^{13}C NMR (101 MHz, CDCl_3): δ = 159.4 (C-5'), 146.6 (C-1), 138.6 (C-1'), 133.5 (C-3'), 129.5 (C-3 and C-5), 119.1 (C-4), 115.3 (C-6'), 114.7 (C-4'), 114.2 (C-2 and C-6), 113.8 (C-2'), 55.6 (5'-OCH₃), 49.3 (1'-CH₂).

HRMS (EI): m/z [M]⁺ calcd for C₁₄H₁₄BrNO⁺: 291.0253; found: 291.0253.

7-Methoxy-2-phenyl-1,2,3,4-tetrahydroisoquinoline (5c)

Prepared according to General Procedure B from *N*-(2-bromo-5-methoxybenzyl)aniline (**3c**) (73.0 mg, 0.250 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (106 μ L, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 95:5) to give product **5c** (29.0 mg, 0.121 mmol, 49%) as a colorless oil.

R_f = 0.27 (hexanes/EtOAc, 95:5).

IR (ATR): 3023, 2907, 2832, 1598, 1501, 1461, 1382, 1319, 1253, 1234, 1147, 1119, 1038, 932, 813, 748, 691 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 7.33–7.27 (m, 2 H, 3'-H and 5'-H), 7.08 (d, J = 8.3 Hz, 1 H, 5-H), 6.99 (dd, J = 8.8, 1.1 Hz, 2 H, 2'-H and 6'-H), 6.87–6.81 (m, 1 H, 4'-H), 6.76 (dd, J = 8.4, 2.7 Hz, 1 H, 6-H), 6.71 (d, J = 2.7 Hz, 1 H, 8-H), 4.39 (s, 2 H, 1-H), 3.81 (s, 3 H, 7-OCH₃), 3.56 (t, J = 5.8 Hz, 2 H, 3-H), 2.92 (t, J = 5.8 Hz, 2 H, 4-H).

^{13}C NMR (101 MHz, CDCl_3): δ = 158.0 (C-7), 150.7 (C-1'), 135.7 (C-8a), 129.6 (C-5), 129.3 (C-3' and C-5'), 127.1 (C-4a), 118.8 (C-4'), 115.4 (C-2' and C-6'), 112.7 (C-6), 111.4 (C-8), 55.5 (7-OCH₃), 51.1 (C-1), 47.0 (C-3), 28.3 (C-4).

HRMS (EI): m/z [M – H]⁺ calcd for C₁₆H₁₆NO⁺: 238.1232; found: 238.1226.

The analytical data are in accordance with those published in the literature.²⁰

***N*-(2-Bromo-4,5-dimethoxybenzyl)aniline (3d)**

Prepared according to General Procedure A from 2-bromo-4,5-dimethoxybenzaldehyde (147 mg, 0.600 mmol) and aniline (**2**) (45.6 μ L, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 80:20) to give product **3d** (126 mg, 0.392 mmol, 78%) as a yellow solid.

R_f = 0.36 (hexanes/EtOAc, 80:20); mp 81–83 °C.

IR (ATR): 3378, 2929, 2837, 1600, 1499, 1434, 1388, 1312, 1255, 1223, 1164, 1099, 1027, 958, 851, 797, 754, 694 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 7.21–7.16 (m, 2 H, 3-H and 5-H), 7.04 (s, 1 H, 3'-H), 6.97 (s, 1 H, 6'-H), 6.78–6.73 (m, 1 H, 4-H), 6.68–6.63 (m, 2 H, 2-H and 6-H), 4.33 (s, 2 H, 1'-CH₂), 3.87 (s, 3 H, 4'-OCH₃ or 5'-OCH₃), 3.79 (s, 3 H, 4'-OCH₃ or 5'-OCH₃).

^{13}C NMR (126 MHz, CDCl_3): δ = 148.8 (C-4' or C-5'), 148.7 (C-4' or C-5'), 147.7 (C-1), 130.2 (C-1'), 129.4 (C-3 and C-5), 118.4 (C-4), 115.7 (C-3'), 113.5 (C-2 and C-6), 113.3 (C-2'), 112.4 (C-6'), 56.4 (4'-OCH₃ or 5'-OCH₃), 56.2 (4'-OCH₃ or 5'-OCH₃), 48.7 (1'-CH₂).

HRMS (EI): m/z [M]⁺ calcd for C₁₅H₁₆BrNO₂⁺: 321.0359; found: 321.0358.

The analytical data are in accordance with those published in the literature.²¹

6,7-Dimethoxy-2-phenyl-1,2,3,4-tetrahydroisoquinoline (5d)

Prepared according to General Procedure B from *N*-(2-bromo-4,5-dimethoxybenzyl)aniline (**3d**) (80.6 mg, 0.250 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (106 μ L, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 75:25) to give product **5d** (36.7 mg, 0.136 mmol, 55%) as a yellow solid.

R_f = 0.45 (hexanes/EtOAc, 75:25); mp 86–90 °C.

IR (ATR): 2920, 2805, 2684, 1599, 1516, 1462, 1450, 1377, 1252, 1209, 1114, 1025, 979, 932, 855, 825, 750, 731, 693 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 7.33–7.27 (m, 2 H, 3'-H and 5'-H), 7.03 (d, J = 7.9 Hz, 2 H, 2'-H and 6'-H), 6.87 (t, J = 7.6 Hz, 1 H, 4'-H), 6.65 (s, 1 H, 5-H or 8-H), 6.65 (s, 1 H, 5-H or 8-H), 4.35 (s, 2 H, 1-H), 3.88 (s, 3 H, 6-OCH₃ or 7-OCH₃), 3.87 (s, 3 H, 6-OCH₃ or 7-OCH₃), 3.56 (t, J = 5.8 Hz, 2 H, 3-H), 2.91 (t, J = 5.8 Hz, 2 H, 4-H).

^{13}C NMR (101 MHz, CDCl_3): δ = 149.6 (C-1'), 147.9 (C-6 or C-7), 147.8 (C-6 or C-7), 129.4 (C-3' and C-5'), 126.5 (C-4a and C-8a), 122.2 (C-4'), 115.9 (C-2' and C-6'), 111.5 (C-5), 109.5 (C-8), 56.13 (6-OCH₃ or 7-OCH₃), 56.08 (6-OCH₃ or 7-OCH₃), 51.0 (C-1), 47.3 (C-3), 28.3 (C-4).

HRMS (EI): m/z [M - H]⁺ calcd for $\text{C}_{17}\text{H}_{18}\text{NO}_2$: 268.1338; found: 268.1332.

The analytical data are in accordance with those published in the literature.²²

2-Bromo-6-methoxy-3-[(phenylamino)methyl]phenol (**3e**)

Prepared according to General Procedure A from 2-bromo-3-hydroxy-4-methoxybenzaldehyde (139 mg, 0.600 mmol) and aniline (**2**) (45.6 μL , 0.500 mmol). The crude product was purified by FCC (DCM/hexanes, 0:100 to 65:35) to give product **3e** (137 mg, 0.445 mmol, 89%) as a beige solid.

R_f = 0.23 (DCM/hexanes, 65:35); mp 86–88 °C.

IR (ATR): 3424, 2840, 1599, 1487, 1435, 1332, 1276, 1232, 1193, 1139, 1030, 987, 947, 810, 741, 689 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 7.21–7.15 (m, 2 H, 3'-H and 5'-H), 6.98 (d, J = 8.4 Hz, 1 H, 4-H), 6.79–6.74 (m, 2 H, 4'-H and 5-H), 6.68 (d, J = 7.8 Hz, 2 H, 2'-H and 6'-H), 4.38 (s, 2 H, CH₂), 3.88 (s, 3 H, OCH₃).

^{13}C NMR (101 MHz, CDCl_3): δ = 146.8 (C-1'), 146.5 (C-6), 143.4 (C-1), 130.4 (C-3), 129.4 (C-3' and C-5'), 120.3 (C-4), 118.8 (C-4'), 114.0 (C-2 and C-6), 109.8 (C-2), 109.6 (C-5), 56.5 (OCH₃), 48.8 (CH₂).

HRMS (EI): m/z [M]⁺ calcd for $\text{C}_{14}\text{H}_{14}\text{BrNO}_2$: 307.0202; found: 307.0201.

6-Methoxy-2-phenyl-1,2,3,4-tetrahydroisoquinolin-5-ol (**5e**)

Prepared according to General Procedure B from 2-bromo-6-methoxy-3-[(phenylamino)methyl]phenol (**3e**) (116 mg, 0.376 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (159 μL , 0.753 mmol). The crude product was purified by FCC (DCM/hexanes, 0:100 to 70:30) to give product **5e** (28.0 mg, 0.110 mmol, 29%) as a yellow solid.

R_f = 0.26 (DCM/hexanes, 70:30); mp 84–86 °C.

IR (ATR): 3457, 2923, 2839, 1598, 1500, 1445, 1392, 1342, 1281, 1228, 1196, 1090, 1043, 1006, 875, 793, 747, 689 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 7.32–7.27 (m, 2 H, 3'-H and 5'-H), 7.03 (d, J = 8.1 Hz, 2 H, 2'-H and 6'-H), 6.86 (t, J = 7.3 Hz, 1 H, 4'-H), 6.75 (d, J = 8.3 Hz, 1 H, 7-H), 6.68 (d, J = 8.3 Hz, 1 H, 8-H), 5.70 (s, 1 H, OH), 4.36 (s, 2 H, 9-H), 3.88 (s, 3 H, OCH₃), 3.57 (t, J = 6.0 Hz, 2 H, 3-H), 2.95 (t, J = 6.0 Hz, 2 H, 4-H).

^{13}C NMR (101 MHz, CDCl_3): δ = 144.6 (C-6), 143.0 (C-5), 129.3 (C-3' and C-5'), 127.9 (C-8a), 121.5 (C-4a), 119.4 (C-4'), 117.3 (C-8), 116.1 (C-2' and C-6'), 108.8 (C-7), 56.3 (C-OCH₃), 50.9 (C-9), 47.0 (C-3), 22.9 (C-4); [C-1' not visible].

HRMS (EI): m/z [M]⁺ calcd for $\text{C}_{16}\text{H}_{17}\text{NO}_2$: 255.1254; found: 255.1260.

4-Bromo-2-methoxy-5-[(phenylamino)methyl]phenol (**3f**)

Prepared according to General Procedure A from 2-bromo-5-hydroxy-4-methoxybenzaldehyde (139 mg, 0.600 mmol) and aniline (**2**) (45.6 μL , 0.500 mmol). The crude product was purified by FCC (DCM/hexanes, 0:100 to 70:30) to give product **3f** (141 mg, 0.458 mmol, 92%) as a brownish solid.

R_f = 0.20 (DCM/hexanes, 70:30); mp 62–63 °C.

IR (ATR): 3475, 2922, 1602, 1497, 1434, 1328, 1269, 1197, 1146, 1034, 861, 822, 797, 745, 692 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 7.21–7.15 (m, 2 H, 3'-H and 5'-H), 7.05 (s, 1 H, 6-H), 7.02 (s, 1 H, 3-H), 6.77 (tt, J = 7.2, 0.8 Hz, 1 H, 4'-H), 6.71–6.66 (m, 2 H, 2'-H and 6'-H), 4.31 (s, 2 H, CH₂), 3.87 (s, 3 H, OCH₃).

^{13}C NMR (101 MHz, CDCl_3): δ = 146.62 (C-2), 146.56 (C-1'), 145.3 (C-1), 130.4 (C-5), 129.4 (C-3' and C-5'), 118.9 (C-4'), 115.7 (C-6), 115.2 (C-3), 114.1 (C-2' and C-6'), 112.5 (C-4), 56.4 (OCH₃), 48.7 (CH₂).

HRMS (EI): m/z [M]⁺ calcd for $\text{C}_{14}\text{H}_{14}\text{BrNO}_2$: 307.0202; found: 307.0200.

6-Methoxy-2-phenyl-1,2,3,4-tetrahydroisoquinolin-7-ol (**5f**)

Prepared according to General Procedure B from 4-bromo-2-methoxy-5-[(phenylamino)methyl]phenol (**3f**) (77.0 mg, 0.376 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (106 μL , 0.500 mmol). The crude product was purified by FCC (DCM/hexanes, 0:100 to 70:30) to give product **5f** (36.0 mg, 0.141 mmol, 56%) as a brownish solid.

R_f = 0.26 (DCM/hexanes, 70:30); mp 96–97 °C.

IR (ATR): 3231, 2942, 2825, 1595, 1529, 1501, 1458, 1376, 1274, 1219, 1203, 1110, 1025, 924, 857, 828, 758, 684 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 7.32–7.27 (m, 2 H, 3'-H and 5'-H), 7.02 (d, J = 8.1 Hz, 2 H, 2'-H and 6'-H), 6.86 (t, J = 6.8 Hz, 1 H, 4'-H), 6.72 (s, 1 H, 8-H), 6.62 (s, 1 H, 5-H), 5.54 (s, 1 H, OH), 4.32 (s, 2 H, 1-H), 3.87 (s, 3 H, OCH₃), 3.55 (t, J = 5.9 Hz, 2 H, 3-H), 2.90 (t, J = 5.9 Hz, 2 H, 4-H).

^{13}C NMR (101 MHz, CDCl_3): δ = 150.5 (C-1'), 145.2 (C-6), 144.0 (C-7), 129.2 (C-3' and C-5'), 127.0 (C-4a or C-8a), 126.1 (C-4a or C-8a), 118.8 (C-4'), 115.4 (C-2' and C-6'), 112.2 (C-8), 110.6 (C-5), 56.0 (OCH₃), 50.4 (C-1), 46.9 (C-3), 28.6 (C-4).

HRMS (EI): m/z [M]⁺ calcd for $\text{C}_{16}\text{H}_{17}\text{NO}_2$: 255.1254; found: 255.1248.

N-(2-Bromo-5-nitrobenzyl)aniline (**3g**)

Prepared according to General Procedure A from 2-bromo-5-nitrobenzaldehyde (138 mg, 0.600 mmol) and aniline (**2**) (45.6 μL , 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 80:20) to give product **3g** (135 mg, 0.440 mmol, 88%) as a yellow solid.

R_f = 0.50 (hexanes/EtOAc, 80:20); mp 123–128 °C.

IR (ATR): 3398, 3089, 2929, 2857, 1602, 1573, 1525, 1493, 1340, 1270, 1239, 1108, 1027, 987, 917, 872, 806, 749, 737, 692 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 8.28 (d, J = 2.8 Hz, 1 H, 6'-H), 7.99 (dd, J = 8.7, 2.8 Hz, 1 H, 4'-H), 7.76 (d, J = 8.6 Hz, 1 H, 3'-H), 7.22–7.14 (m, 2 H, 3-H and 5-H), 6.80–6.73 (m, 1 H, 4-H), 6.61–6.56 (m, 2 H, 2-H and 6-H), 4.48 (s, 2 H, 1'-CH₂).

^{13}C NMR (101 MHz, CDCl_3): δ = 147.8 (C-5'), 147.0 (C-1), 141.0 (C-1'), 133.9 (C-3'), 130.1 (C-2'), 129.6 (C-3 and C-5), 123.7 (C-6'), 123.4 (C-4'), 118.7 (C-4), 113.1 (C-2 and C-6), 48.5 (1'-CH₂).

HRMS (EI): m/z [M]⁺ calcd for $\text{C}_{13}\text{H}_{11}\text{BrN}_2\text{O}_2$: 305.9998; found: 305.9999.

7-Nitro-2-phenyl-1,2,3,4-tetrahydroisoquinoline (5g)

Prepared according to General Procedure B from *N*-(2-bromo-5-nitrobenzyl)aniline (**3g**) (76.8 mg, 0.250 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (106 μ L, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 85:15) to give product **5g** (39.9 mg, 0.157 mmol, 63%) as an orange solid.

R_f = 0.50 (hexanes/EtOAc, 85:15); mp 66–70 °C.

IR (ATR): 2920, 2846, 2774, 1599, 1514, 1493, 1460, 1378, 1340, 1262, 1194, 1086, 931, 891, 813, 756, 733, 695 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 8.07–8.02 (m, 2 H, 6-H and 8-H), 7.34–7.28 (m, 3 H, 3'-H, 5'-H and 5-H), 7.02–6.98 (m, 2 H, 2'-H and 6'-H), 6.89 (tt, J = 7.3, 1.1 Hz, 1 H, 4'-H), 4.48 (s, 2 H, 1-H), 3.61 (t, J = 5.8 Hz, 2 H, 3-H), 3.08 (t, J = 5.8 Hz, 2 H, 4-H).

^{13}C NMR (101 MHz, CDCl_3): δ = 150.1 (C-1'), 146.5 (C-7), 142.8 (C-4a), 136.2 (C-8a), 129.8 (C-5), 129.5 (C-3' and C-5'), 121.9 (C-6 or C-8), 121.5 (C-6 or C-8), 119.8 (C-4'), 115.9 (C-2' and C-6'), 51.0 (C-1), 46.6 (C-3), 29.3 (C-4).

HRMS (EI): m/z [$\text{M} - \text{H}$] $^+$ calcd for $\text{C}_{15}\text{H}_{13}\text{NO}_2$: 253.0977; found: 253.0971.

The analytical data are in accordance with those published in the literature.²³

***N*-(3-Bromothiophen-2-yl)methyl]aniline (3h)**

Prepared according to General Procedure A from 3-bromothiophene-2-carboxaldehyde (115 mg, 0.600 mmol) and aniline (**2**) (45.6 μ L, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 95:5) to give product **3h** (117 mg, 0.438 mmol, 88%) as a yellow liquid.

R_f = 0.47 (hexanes/EtOAc, 95:5).

IR (ATR): 3410, 1600, 1501, 1312, 1259, 1180, 1152, 1095, 1067, 923, 869, 748, 690 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 7.22–7.17 (m, 3 H, 3-H, 5-H and 5'-H), 6.96 (d, J = 5.3 Hz, 1 H, 4'-H), 6.76 (tt, J = 7.4, 1.1 Hz, 1 H, 4-H), 6.70–6.66 (m, 2 H, 2-H and 6-H), 4.48 (d, J = 5.0 Hz, 2 H, 2'-CH₂), 4.14 (s, 1 H, NH).

^{13}C NMR (126 MHz, CDCl_3): δ = 147.4 (C-1), 138.0 (C-2'), 130.2 (C-4'), 129.4 (C-3 and C-5), 124.8 (C-5'), 118.6 (C-4), 113.5 (C-2 and C-6), 108.6 (C-3'), 43.1 (2'-CH₂).

HRMS (EI): m/z [M] $^{+}$ calcd for $\text{C}_{11}\text{H}_{10}\text{BrNS}^{+}$: 266.9712; found: 266.9712.

6-Phenyl-4,5,6,7-tetrahydrothieno[2,3-*c*]pyridine (5h)

Prepared according to General Procedure B from *N*-(3-bromothiophen-2-yl)methyl]aniline (**3h**) (53.6 mg, 0.200 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (84.7 μ L, 0.400 mmol). The crude product was purified by FCC (hexanes/EtOAc, 95:5) to give product **5h** (16.4 mg, 0.0762 mmol, 38%) as a yellow oil.

R_f = 0.26 (DCM/hexanes, 25:75).

IR (ATR): 3318, 2920, 1598, 1497, 1381, 1317, 1244, 1228, 1183, 1127, 994, 886, 750, 690 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 7.30–7.25 (m, 2 H, 3'-H and 5'-H), 7.14 (dt, J = 5.0, 0.8 Hz, 1 H, 2-H), 7.02–6.98 (m, 2 H, 2'-H and 6'-H), 6.86 (tt, J = 7.3, 1.1 Hz, 1 H, 4'-H), 6.81 (d, J = 5.0 Hz, 1 H, 3-H), 4.47–4.45 (m, 2 H, 7-H), 3.62 (t, J = 5.7 Hz, 2 H, 5-H), 2.82 (tt, J = 5.8, 1.7 Hz, 2 H, 4-H).

^{13}C NMR (126 MHz, CDCl_3): δ = 150.6 (C-1'), 134.3 (C-3a), 132.9 (C-7a), 129.4 (C-3' and C-5'), 127.2 (C-3), 122.7 (C-2), 119.6 (C-4'), 116.4 (C-2' and C-6'), 48.3 (C-7), 47.6 (C-5), 25.5 (C-4).

HRMS (EI): m/z [M] $^{+}$ calcd for $\text{C}_{13}\text{H}_{13}\text{NS}^{+}$: 215.0763; found: 215.0763.

***N*-(2-Bromopyridin-3-yl)methyl]aniline (3i)**

Prepared according to General Procedure A from 2-bromo-3-pyridinecarboxaldehyde (112 mg, 0.600 mmol) and aniline (**2**) (45.6 μ L, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 85:15) to give product **3i** (121 mg, 0.460 mmol, 92%) as a beige solid.

R_f = 0.26 (hexanes/EtOAc, 85:15); mp 107–109 °C.

IR (ATR): 3295, 2921, 1600, 1560, 1531, 1496, 1398, 1324, 1276, 1254, 1178, 1051, 987, 860, 800, 745, 689 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 8.27 (dt, J = 4.7, 1.3 Hz, 1 H, 6'-H), 7.69 (ddt, J = 7.6, 1.9, 0.9 Hz, 1 H, 4'-H), 7.22 (dd, J = 7.6, 4.7 Hz, 1 H, 5'-H), 7.20–7.15 (m, 2 H, 3-H and 5-H), 6.75 (tt, J = 7.3, 1.1 Hz, 1 H, 4-H), 6.59–6.55 (m, 2 H, 2-H and 6-H), 4.41 (d, J = 4.6 Hz, 2 H, 3'-CH₂), 4.29 (s, 1 H, NH).

^{13}C NMR (126 MHz, CDCl_3): δ = 148.7 (C-6'), 147.2 (C-1), 142.8 (C-2'), 137.2 (C-4'), 135.8 (C-3'), 129.6 (C-3 and C-5), 123.2 (C-5'), 118.4 (C-4), 113.1 (C-2 and C-6), 47.5 (3'-CH₂).

HRMS (EI): m/z [M] $^{+}$ calcd for $\text{C}_{12}\text{H}_{11}\text{BrN}_2^{+}$: 262.0100; found: 262.0101.

The analytical data are in accordance with those published in the literature.²⁴

***N*-(2-Bromobenzyl)-4-methoxyaniline (3j)**

Prepared according to General Procedure A from 2-bromobenzaldehyde (**1**) (111 mg, 0.600 mmol) and *p*-anisidine (62.2 mg, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 90:10) to give product **3j** (108 mg, 0.369 mmol, 74%) as a dark yellow liquid.

R_f = 0.39 (hexanes/EtOAc, 90:10).

IR (ATR): 3419, 3059, 2995, 2931, 2831, 1618, 1568, 1509, 1464, 1440, 1357, 1232, 1178, 1123, 1082, 1025, 818, 749, 660 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 7.56 (dd, J = 8.0, 1.3 Hz, 1 H, 3'-H), 7.46–7.42 (m, 1 H, 6'-H), 7.29–7.23 (m, 1 H, 5'-H), 7.15–7.10 (m, 1 H, 4'-H), 6.80–6.60 (m, 4 H, 2-H, 3-H, 5-H and 6-H), 4.38 (s, 2 H, 1'-CH₂), 3.74 (s, 3 H, 4-OCH₃).

^{13}C NMR (101 MHz, CDCl_3): δ = 153.0 (C-4), 141.1 (C-1), 138.0 (C-1'), 132.9 (C-3'), 129.7 (C-6'), 128.9 (C-4'), 127.7 (C-5'), 123.6 (C-2'), 115.1 (C-2 and C-6 or C-3 and C-5), 115.0 (C-2 and C-6 or C-3 and C-5), 55.9 (4-OCH₃), 49.8 (1'-CH₂).

HRMS (EI): m/z [M] $^{+}$ calcd for $\text{C}_{14}\text{H}_{14}\text{BrNO}^{+}$: 291.0253; found: 291.0253.

The analytical data are in accordance with those published in the literature.²⁵

2-(4-Methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline (5j)

Prepared according to General Procedure B from *N*-(2-bromobenzyl)-4-methoxyaniline (**3j**) (51.0 mg, 0.175 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (74.2 μ L, 0.350 mmol). The crude product was purified by FCC (hexanes/EtOAc, 85:15) to give product **5j** (22.9 mg, 95.7 μ mol, 55%) as a brown solid.

R_f = 0.58 (hexanes/EtOAc, 85:15); mp 80–84 °C.

IR (ATR): 2920, 2808, 1509, 1459, 1442, 1385, 1272, 1240, 1206, 1188, 1151, 1111, 1035, 930, 822, 800, 754, 720, 701 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 7.21–7.11 (m, 4 H, 5-H, 6-H, 7-H and 8-H), 7.05–6.98 (m, 2 H, 2'-H and 6'-H), 6.90–6.85 (m, 2 H, 3'-H and 5'-H), 4.31 (s, 2 H, 1-H), 3.78 (s, 3 H, 4'-OCH₃), 3.46 (t, J = 5.9 Hz, 2 H, 3-H), 3.00 (t, J = 5.9 Hz, 2 H, 4-H).

^{13}C NMR (101 MHz, CDCl_3): δ = 153.6 (C-4'), 145.5 (C-1'), 134.8 (C-4a or C-8a), 134.7 (C-4a or C-8a), 128.8 (C-5), 126.7 (C-6 or C-7 or C-8), 126.4 (C-6 or C-7 or C-8), 126.0 (C-6 or C-7 or C-8), 118.2 (C-2' and C-6'), 114.7 (C-3' and C-5'), 55.8 (4'-OCH₃), 52.8 (C-1), 48.6 (C-3), 29.2 (C-4).

HRMS (EI): m/z [$M - H$]⁺ calcd for $\text{C}_{16}\text{H}_{16}\text{NO}^+$: 238.1232; found: 238.1226.

The analytical data are in accordance with those published in the literature.^{6c}

Ethyl 4-[(2-Bromobenzyl)amino]benzoate (3k)

Prepared according to General Procedure A from 2-bromobenzaldehyde (**1**) (111 mg, 0.600 mmol) and ethyl-4-aminobenzoate (82.6 mg, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 75:25) to give product **3k** (108 mg, 0.323 mmol, 65%) as a white solid. R_f = 0.47 (hexanes/EtOAc, 75:25); mp 117–120 °C.

IR (ATR): 3374, 2928, 1722, 1672, 1598, 1530, 1439, 1336, 1268, 1173, 1106, 1023, 839, 770, 752, 700 cm^{-1} .

^1H NMR (400 MHz, CDCl_3): δ = 7.91–7.85 (m, 2 H, 2-H and 6-H), 7.57 (dd, J = 7.9, 1.3 Hz, 1 H, 3'-H), 7.41 (d, J = 7.5 Hz, 1 H, 6'-H), 7.29–7.23 (m, 1 H, 5'-H), 7.15 (td, J = 7.6, 1.7 Hz, 1 H, 4'-H), 6.67 (d, J = 8.3 Hz, 2 H, 3-H and 5-H), 4.49 (s, 2 H, 1'-CH₂), 4.31 (q, J = 7.1 Hz, 2 H, 7-H), 1.35 (t, J = 7.1 Hz, 3 H, 8-H).

^{13}C NMR (101 MHz, CDCl_3): δ = 166.8 (1-COOEt), 150.6 (C-4), 136.9 (C-1'), 133.1 (C-3'), 131.6 (C-2 and C-6), 129.4 (C-6'), 129.3 (C-4'), 127.8 (C-5'), 123.6 (C-2'), 120.3 (C-1), 112.7 (C-3 and C-5), 60.5 (C-7), 48.4 (1'-CH₂), 14.6 (C-8).

HRMS (EI): m/z [M]⁺ calcd for $\text{C}_{16}\text{H}_{16}\text{BrNO}_2^+$: 333.0359; found: 333.0358.

The analytical data are in accordance with those published in the literature.²⁶

Ethyl 4-[3,4-Dihydroisoquinolin-2(1H)-yl]benzoate (5k)

Prepared according to General Procedure B from ethyl 4-[(2-bromobenzyl)amino]benzoate (**3k**) (83.6 mg, 0.250 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (106 μL , 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 85:15) to give product **5k** (49.1 mg, 0.175 mmol, 70%) as an off-white solid.

R_f = 0.32 (hexanes/EtOAc, 95:5); mp 49–51 °C.

IR (ATR): 2977, 2850, 1695, 1604, 1519, 1390, 1362, 1277, 1228, 1181, 1102, 1024, 926, 827, 767, 741, 698 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 7.98–7.94 (m, 2 H, 2-H and 6-H), 7.24–7.16 (m, 4 H, 5'-H, 6'-H, 7'-H and 8'-H), 6.91–6.85 (m, 2 H, 3-H and 5-H), 4.52 (s, 2 H, 1'-H), 4.33 (q, J = 7.1 Hz, 2 H, 7-H), 3.66 (t, J = 5.9 Hz, 2 H, 3'-H), 3.00 (t, J = 5.9 Hz, 2 H, 4'-H), 1.38 (t, J = 7.1 Hz, 3 H, 8-H).

^{13}C NMR (126 MHz, CDCl_3): δ = 167.0 (1-COOEt), 153.1 (C-4), 135.2 (C-8'a), 134.0 (C-4'a), 131.4 (C-2 and C-6), 128.4 (C-5'), 126.9 (C-6' or C-7' or C-8'), 126.7 (C-6' or C-7' or C-8'), 126.5 (C-6' or C-7' or C-8'), 118.9 (C-1), 112.3 (C-3 and C-5), 60.4 (C-7), 49.3 (C-1'), 45.0 (C-3'), 29.2 (C-4'), 14.6 (C-8).

HRMS (EI): m/z [$M - H$]⁺ calcd for $\text{C}_{18}\text{H}_{18}\text{NO}_2^+$: 280.1338; found: 280.1332.

The analytical data are in accordance with those published in the literature.²⁷

N-(2-Bromobenzyl)cyclohexanamine (3l)

Prepared according to General Procedure A from 2-bromobenzaldehyde (**1**) (111 mg, 0.600 mmol) and cyclohexylamine (57.8 μL , 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc + Et₃N, 90:10 + 1) to give product **3l** (64.0 mg, 0.239 mmol, 48%) as a colorless oil.

R_f = 0.30 (hexanes/EtOAc, 90:10 + Et₃N).

IR (ATR): 2923, 2851, 1462, 1440, 1347, 1259, 1124, 1024, 888, 746, 656 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 7.53 (dd, J = 7.9, 1.3 Hz, 1 H, 3'-H), 7.40 (dd, J = 7.6, 1.8 Hz, 1 H, 6'-H), 7.27 (td, J = 7.5, 1.1 Hz, 1 H, 5'-H), 7.11 (td, J = 7.7, 1.8 Hz, 1 H, 4'-H), 3.88 (s, 2 H, 1'-CH₂), 2.46 (tt, J = 10.3, 3.7 Hz, 1 H, 1-H), 1.96–1.90 (m, 2 H, 2-H and/or 6-H), 1.77–1.71 (m, 2 H, 3-H and/or 5-H), 1.64–1.58 (m, 1 H, 4-H), 1.31–1.20 (m, 2 H, 2-H and/or 6-H), 1.20–1.10 (m, 3 H, 4-H and 3-H and/or 5-H).

^{13}C NMR (126 MHz, CDCl_3): δ = 140.0 (C-1'), 132.9 (C-3'), 130.5 (C-6'), 128.6 (C-4'), 127.6 (C-5'), 124.1 (C-2'), 56.2 (C-1), 51.1 (1'-CH₂), 33.7 (C-2 and C-6), 26.3 (C-4), 25.2 (C-3 and C-5).

HRMS (EI): m/z [M]⁺ calcd for $\text{C}_{13}\text{H}_{18}\text{BrN}^+$: 267.0617; found: 267.0617.

The analytical data are in accordance with those published in the literature.²⁸

N-(2-Bromobenzyl)-4-chloroaniline (3m)

Prepared according to General Procedure A from 2-bromobenzaldehyde (**1**) (111 mg, 0.600 mmol) and 4-chloroaniline (65.1 mg, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc, 95:5) to give product **3m** (112 mg, 0.379 mmol, 76%) as a pale yellow oil.

R_f = 0.33 (hexanes/EtOAc, 95:5).

IR (ATR): 3430, 2923, 2852, 1599, 1497, 1464, 1440, 1319, 1264, 1177, 1095, 1024, 812, 747 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 7.57 (dd, J = 7.9, 1.2 Hz, 1 H, 3'-H), 7.36 (dq, J = 7.7, 0.8 Hz, 1 H, 6'-H), 7.26 (td, J = 7.5, 1.3 Hz, 1 H, 5'-H), 7.18–7.13 (m, 1 H, 4'-H), 7.13–7.09 (m, 2 H, 3-H and 5-H), 6.55–6.51 (m, 2 H, 2-H and 6-H), 4.38 (d, J = 5.7 Hz, 2 H, 1'-CH₂), 4.22 (t, J = 5.0 Hz, 1 H, NH).

^{13}C NMR (126 MHz, CDCl_3): δ = 146.4 (C-1), 137.8 (C-1'), 133.1 (C-3'), 129.3 (C-3 and C-5), 129.2 (C-6'), 129.0 (C-4'), 127.7 (C-5'), 123.4 (C-2'), 122.5 (C-4), 114.2 (C-2 and C-6), 48.6 (1'-CH₂).

HRMS (EI): m/z [M]⁺ calcd for $\text{C}_{13}\text{H}_{11}\text{BrClN}^+$: 294.9758; found: 294.9758.

2-(4-Chlorophenyl)-1,2,3,4-tetrahydroisoquinoline (5m)

Prepared according to General Procedure B from *N*-(2-bromobenzyl)-4-chloroaniline (**3m**) (59.3 mg, 0.200 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (84.7 μL , 0.400 mmol). The crude product was purified by FCC (hexanes/EtOAc, 98:2) to give product **5m** (33.6 mg, 0.138 mmol, 69%) as a beige solid.

R_f = 0.36 (hexanes/EtOAc, 98:2); mp 59–62 °C.

IR (ATR): 3316, 2915, 2842, 1595, 1494, 1459, 1430, 1384, 1341, 1300, 1224, 1156, 1093, 928, 806, 738, 720 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 7.24–7.21 (m, 2 H, 3'-H and 5'-H), 7.21–7.14 (m, 4 H, 5-H, 6-H, 7-H and 8-H), 6.90–6.87 (m, 2 H, 2'-H and 6'-H), 4.38 (s, 2 H, 1-H), 3.53 (t, J = 5.9 Hz, 2 H, 3-H), 2.98 (t, J = 5.9 Hz, 2 H, 4-H).

^{13}C NMR (126 MHz, CDCl_3): δ = 149.2 (C-1'), 134.8 (C-4a), 134.2 (C-8a), 129.2 (C-3' and C-5'), 128.7 (C-5), 126.7 (C-6 or C-7 or C-8), 126.6 (C-6 or C-7 or C-8), 126.3 (C-6 or C-7 or C-8), 123.5 (C-4'), 116.3 (C-2' and C-6'), 50.8 (C-1), 46.7 (C-3), 29.1 (C-4).

HRMS (EI): m/z [$M - H$] $^+$ calcd for $\text{C}_{15}\text{H}_{13}\text{ClN}^+$: 242.0737; found: 242.0730.

The analytical data are in accordance with those published in the literature.²⁹

N-(2-Bromobenzyl)pyridin-2-amine (3n)

Prepared according to General Procedure A from 2-bromobenzaldehyde (**1**) (111 mg, 0.600 mmol) and 2-aminopyridine (47.1 mg, 0.500 mmol). The crude product was purified by FCC (hexanes/EtOAc + Et_3N , 90:10 + 1) to give product **3n** (62.0 mg, 0.236 mmol, 47%) as a yellow solid.

R_f = 0.25 (hexanes/EtOAc + Et_3N , 90:10 + 1); mp 109–112 °C.

IR (ATR): 3235, 3020, 1600, 1580, 1537, 1448, 1425, 1331, 1277, 1152, 1023, 767, 750 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 8.11 (ddd, J = 5.1, 1.9, 0.9 Hz, 1 H, 6-H), 7.56 (dd, J = 7.9, 1.2 Hz, 1 H, 3'-H), 7.45–7.39 (m, 1 H, 6'-H), 7.40 (ddd, J = 8.7, 7.1, 1.9 Hz, 1 H, 4-H), 7.28–7.24 (m, 1 H, 5'-H), 7.15–7.10 (m, 1 H, 4'-H), 6.60 (ddd, J = 7.1, 5.0, 1.0 Hz, 1 H, 5-H), 6.36 (dt, J = 8.3, 0.9 Hz, 1 H, 3-H), 5.06–5.00 (m, 1 H, NH), 4.59 (d, J = 6.3 Hz, 2 H, 1'- CH_2).

^{13}C NMR (126 MHz, CDCl_3): δ = 158.5 (C-2), 148.3 (C-6), 138.2 (C-1'), 137.7 (C-4), 132.9 (C-3'), 129.4 (C-6'), 128.9 (C-4'), 127.7 (C-5'), 123.6 (C-2'), 113.5 (C-5), 107.0 (C-3), 46.6 (1'- CH_2).

HRMS (EI): m/z [M] $^{++}$ calcd for $\text{C}_{12}\text{H}_{11}\text{BrN}_2^{++}$: 262.0100; found: 262.0100.

2-(Pyridin-2-yl)-1,2,3,4-tetrahydroisoquinoline (5n)

Prepared according to General Procedure B from *N*-(2-bromobenzyl)pyridin-2-amine (**3n**) (52.6 mg, 0.200 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (84.7 μL , 0.400 mmol). The crude product was purified by FCC (hexanes/EtOAc + Et_3N , 90:10 + 1) to give product **5n** (10.1 mg, 0.0480 mmol, 24%) as an off-white oily solid.

R_f = 0.40 (hexanes/EtOAc + Et_3N , 95:5 + 1).

IR (ATR): 3006, 2922, 2837, 1666, 1592, 1562, 1480, 1435, 1387, 1312, 1299, 1228, 1157, 978, 937, 764, 741 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 8.22 (ddd, J = 5.0, 2.0, 0.9 Hz, 1 H, 6'-H), 7.50 (ddd, J = 8.9, 7.1, 2.0 Hz, 1 H, 4'-H), 7.22–7.19 (m, 2 H, 6-H and/or 7-H and/or 8-H), 7.19–7.17 (m, 2 H, 5-H and 6-H or 7-H or 8-H), 6.68 (dt, J = 8.6, 1.0 Hz, 1 H, 3'-H), 6.60 (ddd, J = 7.1, 5.0, 0.9 Hz, 1 H, 5'-H), 4.71 (s, 2 H, 1-H), 3.85 (t, J = 6.0 Hz, 2 H, 3-H), 2.98 (t, J = 5.9 Hz, 2 H, 4-H).

^{13}C NMR (126 MHz, CDCl_3): δ = 158.9 (C-2'), 148.1 (C-6'), 137.6 (C-4'), 135.6 (C-4a), 134.5 (C-8a), 128.5 (C-5), 126.7 (C-8), 126.5 (C-6 or C-7), 126.3 (C-6 or C-7), 112.6 (C-5'), 106.8 (C-3'), 47.3 (C-1), 42.7 (C-3), 29.2 (C-4).

HRMS (EI): m/z [M] $^{++}$ calcd for $\text{C}_{14}\text{H}_{14}\text{N}_2^{++}$: 210.1151; found: 210.1150.

The analytical data are in accordance with those published in the literature.³⁰

Ethyl 3-(3-Bromo-4-[(2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-6-yl)amino]methyl)benzamido)propanoate (3o)

Prepared according to General Procedure A (but with 1.5 equivalents of the aldehyde) from ethyl 3-(3-bromo-4-formylbenzamido)propanoate (**6**) (200 mg, 0.609 mmol) and 6-amino-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (**7**) (78.5 mg, 0.406 mmol). The product **3o** (196 mg, 0.389 mmol, 96%) was obtained without further purification as a yellow oily solid.

R_f = 0.34 (hexanes/EtOAc, 50:50).

IR (ATR): 3369, 2989, 2938, 2322, 2178, 1715, 1648, 1536, 1495, 1378, 1295, 1278, 1196, 1126, 1051, 1035, 980, 934, 826 cm^{-1} .

^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 8.64 (t, J = 5.5 Hz, 1 H, CONH), 8.06 (d, J = 1.7 Hz, 1 H, 2'-H), 7.78 (dd, J = 8.0, 1.7 Hz, 1 H, 6'-H), 7.45 (d, J = 8.0 Hz, 1 H, 5'-H), 6.93 (dd, J = 8.9, 2.8 Hz, 1 H, 7''-H), 6.89 (d, J = 8.7 Hz, 1 H, 8''-H), 6.86 (d, J = 2.7 Hz, 1 H, 5''-H), 6.53 (t, J = 6.0 Hz, 1 H, CH_2NH), 4.33 (d, J = 5.9 Hz, 2 H, CH_2NH), 4.06 (q, J = 7.1 Hz, 2 H, CH_2CH_3), 3.47 (td, J = 6.7, 5.4 Hz, 2 H, 3-H), 2.56 (t, J = 6.9 Hz, 2 H, 2-H), 1.62 [s, 6 H, $\text{C}(\text{CH}_3)_2$], 1.17 (t, J = 7.1 Hz, 3 H, CH_2CH_3).

^{13}C NMR (126 MHz, $\text{DMSO}-d_6$): δ = 171.2 (C-1), 164.6 (CONH), 160.7 (C-4'), 146.7 (C-8a''), 143.9 (C-6''), 141.2 (C-4'), 134.8 (C-1'), 131.1 (C-2'), 128.6 (C-5'), 126.6 (C-6'), 122.4 (C-3'), 121.8 (C-7''), 117.9 (C-8''), 113.5 (C-4a''), 109.3 (C-5''), 105.9 (C-2''), 59.9 (CH_2CH_3), 47.1 (CH_2NH), 35.6 (C-3), 33.6 (C-2), 25.2 [$\text{C}(\text{CH}_3)_2$], 14.1 (CH_2CH_3).

HRMS (ESI): m/z [$M - H$] $^-$ calcd for $\text{C}_{23}\text{H}_{24}\text{BrN}_2\text{O}_6^-$: 503.0823; found: 503.0827.

5-[6-[(2-Carboxyethyl)carbonyl]-3,4-dihydroisoquinolin-2(1H)-yl]-2-hydroxybenzoic Acid (5o)

Prepared according to General Procedure B from ethyl 3-(3-bromo-4-[(2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-6-yl)amino]methyl)benzamido)propanoate (**3o**) (150 mg, 0.208 mmol) and (*E*)-2-ethoxyvinylboronic acid pinacol ester (88.0 μL , 0.416 mmol).

Without purification, the crude cyclized product (0.208 mmol) was then dissolved in THF (1.4 mL) followed by the addition of a solution of KOH (58.3 mg, 1.04 mmol) in water (1.4 mL). The reaction mixture was stirred at room temperature for 1.5 h. Then water (10 mL) was added and the mixture acidified to pH 1 using 2 N aq HCl. The organic material was extracted with EtOAc (3 $\times$ 15 mL). The combined organic layers were extracted with 0.5 M aq NaOH (3 $\times$ 15 mL). The aqueous phase was then again acidified to pH 1 using 2 M aq HCl and extracted with EtOAc (3 $\times$ 15 mL). The combined organic layers were dried using phase separating paper and the solvents were removed in vacuo. The crude product was purified by FCC (MeOH/DCM + AcOH, 5:95 + 1) and dried under high vacuum to give **5o** (47.9 mg, 0.125 mmol, 60% over 3 steps) as a yellow-brown oily solid.

R_f = 0.14 (MeOH/DCM + AcOH, 5:95 + 1).

IR (ATR): 3333, 2922, 2586, 1709, 1632, 1547, 1488, 1434, 1372, 1229, 1009, 828, 750 cm^{-1} .

^1H NMR (500 MHz, $\text{DMSO}-d_6$): δ (contains residual AcOH) = 12.22 (s, 2 H, 1-COOH and 2''-COOH), 8.46 (t, J = 5.4 Hz, 1 H, CONH), 7.64 (s, 1 H, 5'-H or 7'-H), 7.64–7.61 (m, 1 H, 5'-H or 7'-H), 7.40 (s, 1 H, 6-H), 7.28 (d, J = 7.9 Hz, 1 H, 8'-H), 7.10 (dd, J = 9.2, 2.7 Hz, 1 H, 4-H), 6.69 (d, J = 8.7 Hz, 1 H, 3-H), 4.23 (s, 2 H, 1'-H), 3.45 (q, J = 6.7 Hz, 2 H, 1''-H), 3.36 (t, J = 5.8 Hz, 3 H, 3'-H), 2.95 (t, J = 5.8 Hz, 2 H, 4'-H), 2.53 [d, J = 1.6 Hz, 2 H, 2''-H (collapses with DMSO)].

^{13}C NMR (126 MHz, $\text{DMSO}-d_6$): δ (contains residual AcOH) = 172.9 (C-3''), 171.8 (1-COOH), 166.2 (CONH), 156.2 (C-2), 141.8 (C-5), 138.1 (C-8a'), 134.3 (C-4a'), 132.3 (C-6'), 127.4 (C-5'), 126.5 (C-8'), 124.5 (C-7'),

122.8 (C-4), 117.6 (C-6), 116.4 (C-3), 52.3 (C-1'), 48.2 (C-3'), 35.6 (C-1''), 33.8 (C-2''), 28.6 (C-4''); [C-1' not clearly visible].

HRMS (ESI): m/z [M – H][–] calcd for C₂₀H₁₉N₂O₆[–]: 383.1249; found: 383.1249.

Funding Information

This work was funded by the Deutsche Forschungsgemeinschaft (DFG) (German Research Foundation) (Project-ID: 325871075-SFB 1309).

Acknowledgment

We thank Doreen Reuter and Karl Sauvageot-Witzku for technical support.

Supporting Information

Supporting information for this article is available online at <https://doi.org/10.1055/s-0040-1706002>.

References

- (1) (a) *The Chemistry and Biology of Isoquinoline Alkaloids*; Phillipson, J. D.; Roberts, M. F.; Zenk, M. H., Ed.; Springer-Verlag: Berlin, **1985**. (b) Qing, Z.-X.; Huang, J.-L.; Yang, X.-Y.; Liu, J.-H.; Cao, H.-L.; Xiang, F.; Cheng, P.; Zeng, J.-G. *Curr. Med. Chem.* **2018**, *25*, 5088.
- (2) (a) Lubisch, W.; Moeller, A.; Treiber, H.-J.; Knopp, M. US6482832B1, **2002**. (b) Burke, P. J.; Wong, L. C.; Jenkins, T. C.; Knox, R. J.; Stanforth, S. P. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 7447. (c) Kalgutkar, A. S.; Frederick, K. S.; Chupka, J.; Feng, B.; Kempshall, S.; Mireles, R. J.; Fenner, K. S.; Troutman, M. D. *J. Pharm. Sci.* **2009**, *98*, 4914. (d) Vernier, J.-M.; De La Rosa, M. A.; Chen, H.; Wu, J. Z.; Larson, G. L.; Cheney, I. W. (e) Buchanan, J. L.; Bregman, H.; Chakka, N.; Dimauro, E. F.; Du, B.; Nguyen, H. N.; Zheng, X. M. WO2010022055A2, **2010**.
- (3) (a) Barlaam, B.; Dantzman, C. WO200246164A1, **2002**. (b) Adams, G. L.; Cox, J. M.; Debenham, J. S.; Edmondson, S.; Gilbert, E.; Guo, Y.; Jiang, Y.; Josien, H.; Kim, H. M.; Lan, P.; Miao, S.; Plummer, C. W.; Rajagopalan, M.; Shah, U.; Sun, Z.; Suzuki, T.; Truong, Q. T.; Ujjainwalla, F.; Velazquez, F.; Venkatraman, S.; Wang, N. WO2017201683A1, **2017**. (c) Funke, U.; Fischer, S.; Hiller, A.; Scheunemann, M.; Deuther-Conrad, W.; Brust, P.; Steinbach, J. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4727.
- (4) (a) Álvarez, M.; Joule, J. A. *Product Class 5: Isoquinolines*, In *Section 15.5, Science of Synthesis: Category 2, Hetarenes and Related Ring Systems, Vol. 15*; Black, D. StC., Ed.; Georg Thieme Verlag: Stuttgart, **2005**, 661. (b) Chrzanowska, M.; Grajewska, A.; Rozwadowska, M. D. *Chem. Rev.* **2016**, *116*, 12369.
- (5) Reimann, E.; Höglmüller, A. *Arch. Pharm.* **1985**, *318*, 559.
- (6) (a) Buckley, B. R.; Christie, S. D. R.; Elsegood, M. R. J.; Gillings, C. M.; Page, P. C. B.; Pardoe, W. J. M. *Synlett* **2010**, 939. (b) Forni, J. A.; Brzozowski, M.; Tsanaksidis, J.; Savage, G. P.; Polyzos, A. *Aust. J. Chem.* **2015**, *68*, 1890. (c) Li, Z.; Li, C.-J. *J. Am. Chem. Soc.* **2005**, *127*, 6968. (d) Quach, T. D.; Batey, R. A. *Org. Lett.* **2003**, *5*, 4397. (e) Ueda, H.; Yoshida, K.; Tokuyama, H. *Org. Lett.* **2014**, *16*, 4194.
- (7) (a) Hodson, H. F.; Batchelor, J. F.; Selway, J. W. T.; Vinter, J. G.; Iyer, R. US4801593, **1989**. (b) Almendra, J.; Foubelo, F.; Yus, M. *Tetrahedron* **1996**, *52*, 8545. (c) Ma, Y.-N.; Yang, X.-J.; Pan, L.; Hou, Z.; Geng, H.-L.; Song, X.-P.; Zhou, L.; Miao, F. *Chem. Pharm. Bull.* **2013**, *61*, 204.
- (8) Mottinelli, M.; Leese, M. P.; Potter, B. V. L. *Beilstein J. Org. Chem.* **2017**, *13*, 1871.
- (9) (a) Schütz, R.; Meixner, M.; Antes, I.; Bracher, F. *Org. Biomol. Chem.* **2020**, *18*, 3047. (b) Schütz, R.; Schmidt, S.; Bracher, F. *Tetrahedron* **2020**, *76*, 131150. (c) Schütz, R.; Müller, M.; Gerndt, S.; Bartel, K.; Bracher, F. *Arch. Pharm.* **2020**, *353*, e2000106. (d) Schütz, R.; Müller, M.; Geisslinger, F.; Vollmar, A.; Bartel, K.; Bracher, F. *Eur. J. Med. Chem.* **2020**, *207*, 112810. (e) Melzer, B. C.; Bracher, F. *Beilstein J. Org. Chem.* **2017**, *13*, 1564. (f) Melzer, B. C.; Felber, J. G.; Bracher, F. *Beilstein J. Org. Chem.* **2018**, *14*, 130. (g) Melzer, B.; Bracher, F. *Org. Biomol. Chem.* **2015**, *13*, 7664.
- (10) Glas, C.; Dietschreit, J. C. B.; Wössner, N.; Urban, L.; Ghazy, E.; Sippl, W.; Jung, M.; Ochsenfeld, C.; Bracher, F. *Eur. J. Med. Chem.* **2020**, *206*, 112676.
- (11) Kamlah, A.; Bracher, F. *Lett. Org. Chem.* **2019**, *16*, 931.
- (12) (a) Vögerl, K.; Ong, D. N.; Bracher, F. *Synthesis* **2018**, *50*, 1323. (b) Bracher, F. *SynOpen* **2018**, *2*, 96. (c) Vögerl, K.; Ong, N.; Senger, J.; Herp, D.; Schmidtkunz, K.; Marek, M.; Müller, M.; Bartel, K.; Shaik, T. B.; Porter, N. J.; Robaa, D.; Christianson, D. W.; Romier, C.; Sippl, W.; Jung, M.; Bracher, F. *J. Med. Chem.* **2019**, *62*, 1138.
- (13) Popp, T. A.; Uhl, E.; Ong, D. N.; Dittrich, S.; Bracher, F. *Tetrahedron* **2016**, *72*, 1668.
- (14) (a) Zhang, X.-L.; Yu, P.; Wu, Y.-W.; Wu, Q.-P.; Zhang, Q.-S. *J. Chem. Res.* **2014**, *38*, 261. (b) Chen, B.-C.; Sundeen, J. E.; Guo, P.; Bednarz, M. S.; Zhao, R. *Tetrahedron Lett.* **2001**, *42*, 1245.
- (15) Barder, T. E.; Walker, S. D.; Martinelli, J. R.; Buchwald, S. L. *J. Am. Chem. Soc.* **2005**, *127*, 4685.
- (16) Sakamoto, T.; Kondo, Y.; Yasuhara, A.; Yamanaka, H. *Tetrahedron* **1991**, *47*, 1877.
- (17) For related observations on *N*-methylations using 1,3,5-trioxane and triethylsilane/TFA, see: Popp, T. A.; Bracher, F. *Synthesis* **2015**, *47*, 3333.
- (18) Swinnen, D.; Gerber, P.; Gonzalez, J.; Bombrun, A.; Jorand-Lebrun, C. WO2005012280A1, **2005**.
- (19) (a) Earley, R. A.; Gallagher, M. J. *J. Organomet. Chem.* **1969**, *20*, 117. (b) Jiang, M.; Li, J.; Wang, F.; Zhao, Y.; Zhao, F.; Dong, X.; Zhao, W. *Org. Lett.* **2012**, *14*, 1420.
- (20) Xu, Y.; Xu, Z.-J.; Liu, Z.-P.; Lou, H. *Org. Chem. Front.* **2019**, *6*, 3902.
- (21) Gaertzen, O.; Buchwald, S. L. *J. Org. Chem.* **2002**, *67*, 465.
- (22) Sud, A.; Sureshkumar, D.; Klusmann, M. *Chem. Commun.* **2009**, 3169.
- (23) Wang, J.; Sun, Y.; Wang, G.; Zhen, L. *Eur. J. Org. Chem.* **2017**, 6338.
- (24) Chen, K.; Pullarkat, S. A. *Org. Biomol. Chem.* **2012**, *10*, 6600.
- (25) Baechler, S. A.; Fehr, M.; Habermeyer, M.; Hofmann, A.; Merz, K.-H.; Fiebig, H.-H.; Marko, D.; Eisenbrand, G. *Bioorg. Med. Chem.* **2013**, *21*, 814.
- (26) Hindley, R. M.; Baggaley, K. H. US4362892A, **1982**.
- (27) Kang, X.; Wu, X.; Han, X.; Yuan, C.; Liu, Y.; Cui, Y. *Chem. Sci.* **2020**, *11*, 1494.
- (28) Oishi, S.; Yoshimoto, J.; Saito, S. *J. Am. Chem. Soc.* **2009**, *131*, 8748.
- (29) Brzozowski, M.; Forni, J. A.; Paul Savage, G.; Polyzos, A. *Chem. Commun.* **2015**, *51*, 334.
- (30) Dastbaravardeh, N.; Schnürch, M.; Mihovilovic, M. D. *Eur. J. Org. Chem.* **2013**, 2878.